Apalutamide: First Global Approval

被引：52

作者：

Al-Salama, Zaina T. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2018年 / 78卷 / 06期

关键词：

RESISTANT PROSTATE-CANCER; ANTITUMOR-ACTIVITY; ARN-509; ANTIANDROGEN; SAFETY;

D O I：

10.1007/s40265-018-0900-z

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Apalutamide (Erleada (TM)) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC). It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens. In February 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC). Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochemically-relapsed PC. This article summarizes the milestones in the development of apalutamide leading to this first approval in nmCRPC.

引用

页码：699 / 705

页数：7

共 14 条

[11] Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management [J].

Rozet, Francois ;

Roumeguere, Thierry ;

Spahn, Martin ;

Beyersdorff, Dirk ;

Hammerer, Peter .

WORLD JOURNAL OF UROLOGY, 2016, 34 (11) :1505-1513

[12] Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer [J].

Smith, Matthew R. ;

Saad, Fred ;

Chowdhury, Simon ;

Oudard, Stephane ;

Hadaschik, Boris A. ;

Graff, Julie N. ;

Olmos, David ;

Mainwaring, Paul N. ;

Lee, Ji Youl ;

Uemura, Hiroji ;

Lopez-Gitlitz, Angela ;

Trudel, Geralyn C. ;

Espina, Byron M. ;

Shu, Youyi ;

Park, Youn C. ;

Rackoff, Wayne R. ;

Yu, Margaret K. ;

Small, Eric J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15) :1408-1418

[13] Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort [J].

Smith, Matthew R. ;

Antonarakis, Emmanuel S. ;

Ryan, Charles J. ;

Berry, William R. ;

Shore, Neal D. ;

Liu, Glenn ;

Alumkal, Joshi J. ;

Higano, Celestia S. ;

Maneval, Edna Chow ;

Bandekar, Rajesh ;

de Boer, Carla J. ;

Yu, Margaret K. ;

Rathkopf, Dana E. .

EUROPEAN UROLOGY, 2016, 70 (06) :963-970

[14]

US FDA, 2018, ERL AP PRESCR INF

← 1 2 →